Laurie Sehn

CAR-T vs bispecific antibodies for lymphoma 12:15
CAR-T vs bispecific antibodies for lymphoma
David Maloney et al.
Will knowledge of the molecular pathology of lymphoma improve clinical trials? 11:43
Will knowledge of the molecular pathology of lymphoma improve clinical trials?
David Maloney et al.
Novel targets and agents for lymphoma 7:45
Novel targets and agents for lymphoma
John Kuruvilla et al.
A breakthrough therapy: polatuzumab vedotin plus BR for R/R DLBCL 5:00
A breakthrough therapy: polatuzumab vedotin plus BR for R/R DLBCL
Laurie Sehn • 16 Jun 2018
iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al.
Novel lymphoma targets and agents
Andrew Zelenetz et al.
Results of trial on the use of interim PET scan to identify DLBCL 3:06
Results of trial on the use of interim PET scan to identify DLBCL
Laurie Sehn • 23 Sep 2016
The standard of care for DLBCL and double-hit lymphoma 1:34
The standard of care for DLBCL and double-hit lymphoma
Laurie Sehn • 23 Sep 2016
Recognizing the heterogeneity of DLBCL 1:06
Recognizing the heterogeneity of DLBCL
Laurie Sehn • 23 Sep 2016
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals